No Data
No Data
Honz Pharmaceutical (300086.SZ) has appointed Han Dingfu as the Chief Financial Officer.
Honz Pharmaceutical (300086.SZ) announced that the board of directors has agreed to appoint Han Dingfu as the company's chief financial officer, with a term starting from...
Little Excitement Around Honz Pharmaceutical Co., Ltd.'s (SZSE:300086) Revenues As Shares Take 27% Pounding
Kangzhi Pharmaceutical (300086.SZ) announced first-quarter results, with a net loss of 46.5 million yuan, which changed from profit to loss over the previous year
Kangzhi Pharmaceutical (300086.SZ) disclosed its report for the first quarter of 2024. The company achieved revenue of 1.0 during the reporting period...
Kangzhi Pharmaceutical (300086.SZ): Currently mainly selling children's medicines include pediatric antipyretic patches, pediatric detoxifying granules, etc.
Gelonghui, March 8 | Kangzhi Pharmaceutical (300086.SZ) recently said during a survey of institutional investors that the company currently mainly sells levocetirizine hydrochloride granules (exclusive dosage form), ibuprofen granules, pediatric antipyretic patches, pediatric antipyretic granules, ammoniacin granules, aminophen yellow nanamine granules, yinhu cold powder, montmorillonite powder, tannic acid protein yeast powder, lactic acid bacterin granules, gastrointestinal dispersion, Zierling granules, Jianlemeng granules Decalcification powder, cough relief orange red granules, carboxymethane granules, pediatric phlegm granules, pediatric phlegm relief granules, head faclor granules, ribavirin
Kangzhi Pharmaceutical (300086.SZ): Injectable sulamine sodium is a product the company is developing and has not yet been marketed for sale
Gelonghui, January 12 | Kangzhi Pharmaceutical (300086.SZ) said on the investor interactive platform that injectable sulamine sodium is a product the company is developing and has not yet been marketed for sale. At that time, the research report on the “Horizontal Research Project Research Cooperation Agreement” between the company and the Guangdong Provincial Institute of Public Health had already been released.
Kangzhi Pharmaceutical (300086.SZ): Up to now, no PEEK-related material products have been produced
Gelonghui, January 12 | Kangzhi Pharmaceutical (300086.SZ) said on the investor interactive platform that currently, the company is a leading domestic children's health enterprise whose main business is the R&D, production and sales of children's medicines, maternal and child health products, and medical devices such as medical protective equipment. The company is closely following the development direction of cutting-edge technology. Up to now, it has not produced PEEK-related material products. Thank you!
No Data